Based on this, this study identified a therapeutic strategy consisting of a combination of small molecule methyltransferase inhibitors and blocking monoclonal antibodies that target both ligands and receptors of the CD155-TIGIT axis, significantly increasing the anti-tumor effect of NK cells. The gene discussed is PVR; the disease is neoplasm.